Azienda USL Toscana Sud Est

At Azienda USL Toscana Sud Est in Arezzo, clinical trials in cardiovascular diseases and nutritional and metabolic diseases focus on conditions such as acute myocardial infarction, atrial fibrillation, heart failure, cardiomyopathy, atherosclerotic cardiovascular disease, and type 2 diabetes. These studies are mainly aimed at testing new treatments, improving prevention, and reducing the risk of major heart and vascular events.

• Research on acute myocardial infarction and coronary syndromes
• Studies in heart failure, cardiomyopathy, and related inflammatory conditions
• Trials in atrial fibrillation and broader cardiovascular risk reduction

The site is also involved in work on metabolic disorders and cardiovascular prevention, including evaluations of therapies designed to better control long-term outcomes in people with established vascular disease.

A major part of the trial portfolio at this hospital/clinic research site centers on neoplasms, with studies in breast cancer, lung cancer, urothelial cancer, renal cell carcinoma, prostate cancer, colorectal cancer, ovarian cancer, hepatocellular carcinoma, and bladder cancer. The research is largely aimed at evaluating new cancer therapies, improving survival, and refining treatment strategies across both early and advanced disease.

• Trials in breast cancer and ovarian cancer, including recurrence prevention and maintenance treatment
• Studies in lung cancer, renal cell carcinoma, and urothelial cancer for advanced disease management
• Research in colorectal cancer, prostate cancer, and hepatocellular carcinoma to improve treatment effectiveness

The oncology program also includes work on immunotherapy, targeted therapy, and perioperative treatment, reflecting a broad effort to personalize cancer care.

In Dermatologia, the site conducts trials in skin and connective tissue diseases and immune system diseases, with attention to atopic dermatitis, actinic keratosis, and diabetic foot ulcers. These studies are designed to test new therapies, support wound healing, and improve symptom control in chronic skin conditions.

• Studies in moderate to severe atopic dermatitis aimed at improving disease control
• Research on actinic keratosis to reduce the risk of progression to skin cancer
• Trials for diabetic foot ulcers focused on wound closure and better healing outcomes

This area highlights the site’s interest in both dermatologic treatment and immune-related inflammation, with a strong practical focus on patient comfort and long-term skin health.

Another prominent field at Azienda USL Toscana Sud Est involves male urogenital diseases and kidney-related conditions, including renal cell carcinoma, urothelial carcinoma, bladder cancer, prostate cancer, and IgA nephropathy. The main goal of these trials is to assess new treatment options, improve disease control, and support better outcomes after surgery or during advanced disease.

• Trials in renal cell carcinoma and advanced kidney cancer
• Studies in bladder cancer and urothelial carcinoma across non-muscle invasive and metastatic settings
• Research in prostate cancer and IgA nephropathy to refine treatment effectiveness

This portfolio combines oncology and nephrology, showing a strong interest in both cancer care and kidney disease management.

The site also supports trials in nervous system diseases, respiratory tract diseases, and virus diseases, including Parkinson's disease, severe viral lung infections, and respiratory conditions requiring diagnostic procedures. These studies aim to improve symptom management, evaluate supportive care, and strengthen diagnostic and treatment approaches in complex medical conditions.

• Research in Parkinson's disease focused on motor symptom control
• Studies of severe viral lung infections and other respiratory disorders
• Trials supporting better diagnostics and clinical care in mixed medical conditions

Together, these studies show a broad commitment to neurologic care, respiratory medicine, and infectious disease research alongside the site’s larger oncology and cardiovascular programs.